| Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. | |
| | |
MedLine Citation:
|
PMID: 23292866 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Aberrant miR-199a-3p expression has been reported in several cancers. However, the clinical significance of miR-199a-3p in human colorectal cancer has not been addressed. In this study, we detected miR-199a-3p expression in 92 colorectal cancer cases to evaluate its clinicopathologic characteristics in colorectal cancer. We showed that miR-199a-3p expression was significantly upregulated in cancer tissues than NATs. Clinicopathologic analysis revealed that high miR-199a-3p expression contributed to more advanced lymphatic invasion, lymph node metastasis, liver metastases and late TNM stage in colorectal cancer. Kaplan-Meier analysis showed that high expression of miR-199a-3p could lead to a significantly shorter overall survival rate. Cox's proportional hazards model also indicated that the high expression of miR-199a-3p could serve as an independent and significant prognostic factor for survival. We transfected miR-199a-3p inhibitor into SW480 cells and observed that miR-199a-3p inhibitor could markedly inhibit the cell proliferation. Flow cytometry analysis also found that miR-199a-3p inhibitor could cause G0/G1 arrest, decreased percentage of S and G2/M phase and induce more cell apoptosis in SW480 cells. These results suggested that miR-199a-3p may serve as an efficient biomarker for diagnosis and novel prognostic indicator in colorectal cancer. |
| | |
Authors:
|
Daiwei Wan; Songbing He; Binhui Xie; Guohui Xu; Wen Gu; Chenglong Shen; You Hu; Xinsheng Wang; Qiaoming Zhi; Liang Wang |
Related Documents
:
|
23474496 - Novel ternary vanadium-betaine-peroxido species suppresses h-ras and matrix metalloprot... 22983756 - Single-agent therapy with sorafenib or 5-fu is equally effective in human colorectal ca... 23335066 - The use of a novel muc1 antibody to identify cancer stem cells and circulating muc1 in ... 23551096 - Achieving cancer cell death with pi3k/mtor-targeted therapies. 23474496 - Novel ternary vanadium-betaine-peroxido species suppresses h-ras and matrix metalloprot... 9889806 - A novel colon pouch and its comparison with a straight coloanal and colon j-pouch--anal... |
Publication Detail:
|
Type: Journal Article Date: 2013-01-06 |
Journal Detail:
|
Title: Medical oncology (Northwood, London, England) Volume: 30 ISSN: 1559-131X ISO Abbreviation: Med. Oncol. Publication Date: 2013 Mar |
Date Detail:
|
Created Date: 2013-01-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9435512 Medline TA: Med Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 378 Citation Subset: IM |
Affiliation:
|
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma.
Next Document: New progress of non-surgical treatments for hepatocellular carcinoma.